was developed with an enhanced capacity to freeze target tissue and to do so over the entire distal hemisphere of the balloon rather than over an equatorial band, as with the first-generation device (2) . Initial studies comparing the first and second generation devices confirmed improved acute (3, 4) and long-term (5) outcomes, consistent with enhanced creation of durable PV isolation (6) .
The advantage of the CB-A is that it can ablate large regions of tissue to achieve PV isolation with a "one-shot freeze"; however, it necessarily follows that this device provides very limited capability for operators to direct more or less ablation to specific sectors of the targeted PV ostium. Although the operator can adjust the orientation of the balloon to some extent relative to the PV and, in so doing, alter the balloon-tissue contact pattern and the distribution of heat removal around the circumference of the PV ostium, user-determined locationspecific delivery of cryothermy ablation is not possible and "over-ablation" at some sites is likely.
Indeed, inadvertent injury of the right phrenic nerve (PN), which courses near the right PV ostia (7, 8) , has emerged as the most common clinically significant complication of cryoballoon ablation. PN injury had previously been reported in only 0.48% of subjects undergoing radiofrequency ablation (9) but was seen in 11.2% of subjects in STOP-AF (1). Not surprisingly, initial studies comparing the "more powerful" CB-A to the first generation cryoballoon revealed an approximate doubling of acute (from 12.6% to 19.5%) and persistent (from 5.4% to 7.3% [beyond discharge from the index procedure]) PN injury (3, 4) and an increase in what had been the rare occurrence of PN injury during ablation at the right inferior PV (10).
Various techniques have been proposed to minimize the risk of PN injury during CB-A ablation.
Several case series describe exclusive use of the large 28-mm CB-A, which minimizes the likelihood that the balloon catheter will be advanced into the right superior PV (5, (11) (12) (13) (14) (15) , and more recent reports describe shortening the delivery time to 180 s and avoiding "bonus" ablation after isolation is achieved (5,16). Monitoring diaphragmatic compound motor action potential (CMAP) amplitude has also been reported as a valuable adjunct to palpating diaphragmatic contraction during PN pacing. CMAP can be measured using surface electrocardiography leads placed at the costophrenic angle (17, 18) or by intravascular recording from the subdiaphragmatic hepatic vein (19) , and may allow for improved sensitivity to identify onset of PN injury and facilitate early discontinuation of cryothermy ablation Preventing Phrenic Nerve Injury A U G U S T 2 0 1 6 : 5 1 5 -7
